BackGlenmark appoints new head for global API and US generic businesses
Philip Andrew Gioia has more than 25 years of experience in the US pharma industry
Premium
Mumbai: Glenmark Pharmaceuticals Ltd. said on Monday that it had named Philip Andrew Gioia as president of its business in North America and also the global bulk drug (active pharma ingredients) business. Gioia has already taken charge of his responsibilities and will be reporting to chairman and managing director Glenn Saldanha from the US.
Gioia has more than 25 years of experience in the US pharmaceutical industry both in the generics and the branded space. He joins Glenmark from Bausch and Lomb, which was acquired by Valeant Pharmaceuticals Inc. in August 2013. Prior to that, Gioia was with Barr Pharmaceuticals Inc., said a Glenmark statement on Monday.
“We believe that with Phil’s rich and diversified experience across the generics and branded pharmaceutical businesses as well as business development, brings the necessary skills and acumen to lead and grow the North American operations and the API business of Glenmark," Saldanha said.
Mumbai-based Glenmark, which has a significant presence in branded generics markets across emerging economies including India, has 14 manufacturing facilities in four countries and has six research and development centres. Its subsidiary, Glenmark Generics Ltd. services the US and Western Europe generics markets, and its API business is spread across over 80 countries, including the US, various countries in the European Union, South America and India.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
